CheckMan Stock Market Overview

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

Celestica (CLS) is expected to witness a top-line expansion year over year in the first quarter of 2024, backed by healthy demand in its networking portfolio.

Apple (AAPL) on Tuesday announced a May 7 event, with the tagline "Let loose," where the company is expected to unveil its latest iPad models.

CLO ETFs offer investors strong yields with little credit or interest rate risk. These are variable rate ETFs, and should see declining dividends as the Fed cuts rates. I still think they are buys, for three key reasons.

WEX's first-quarter 2023 revenues are expected to benefit from segmental strength.

SBA Communications' (SBAC) Q1 earnings are likely to have benefited from the robust demand for its wireless communication assets by carriers, though high interest expenses may have hurt it.

When you look at the technology, it's hard not to be bullish on the future of electric vehicles. The environmental impact alone should be enough to realize that EV adoption will continue to rise as time goes on.

Novartis AG (ADR) (NYSE:NVS) has raised its full-year revenue and profit guidance following a strong first quarter driven by momentum in key products including psoriasis drug Cosentyx, relapsing Multiple Sclerosis medicine Kesimipta and high cholesterol drug Leqvio. The Swiss drugmaker expects its 2024 sales to grow in the high-single to low-double-digit percentage range, compared to its earlier expectation of a mid-single-digit increase.

Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's "Halftime Report" to discuss the stock's recent performance.

Jason Snipe, founder and CIO at Odyssey Capital Advisors, joins CNBC's "Halftime Report" to discuss his most recent portfolio move.